

**Audrey's Life Science Meeting Picks for Sept. 3, 2017 – Oct. 2017  
Complimentary Service of AudreysNetwork.com**

\*\*\*\*\*

**Bio2Device Group, Tuesday Morning, Sept. 5, 2017**

Topic: "The Journey to Mars: The Next Giant Leap for All Mankind"

Speaker: Elizabeth Keller, Science Manager, Space Biology Project, NASA

Date and Time: Tuesday, Sept. 5, 2017 – 8:30 am

Location: Sunnyvale City Council Chambers- 456 West Olive Ave., Sunnyvale

There is no registration or cost for morning meetings.

**Topic Description**

Since we first landed on the moon in 1969, the world has been captivated by the exploration of this last frontier and the promising new discoveries that await. Sending robotic probes and roving satellites into space has captured fascinating new finds that delight and inspire, but nothing quite captures the imagination as the notion of sending humans into the inhospitable vastness of space. The Journey to Mars is an enormous undertaking that involves thousands of experts in science, engineering, and technology working collaboratively to identify and solve seemingly impossible challenges, configure, test and build pioneering new technologies, and eventually take a giant calculated leap of faith into the Great Beyond. Many doubt it will be possible, many more question the value of trying, but those of us involved in the effort are thrilled with the opportunity to tread where no one has gone before and create advances in medicine and technology that will benefit all of humanity."

**Speaker Bio**

Elizabeth has had a colorful career working as a scientist, in technology, as a business owner, and an award-winning author. She started her career in science as a graduate student at Ames Research Center working in Aerospace Human Factors conducting research on astronauts working in low earth orbit. She soon after went to work in the Space Life Sciences Payloads Office where she worked supporting science payload operations on the Space Shuttle. She is the creator, author and producer of ExtremeScience.com, an online destination that established a new standard for approachable and engaging science education. Her success with Extreme Science got her noticed by the National Geographic Society, which later offered her a book contract. She's been back at Ames Research Center since 2012 as a Senior Scientist supporting the Space Biology project office, where she is a science manager supporting strategic planning for life sciences research in space. Elizabeth enjoys engaging the public on NASA's missions and inspiring the next generation.

\*\*\*\*\*

**AWIS SF, Wednesday Evening, Sept. 6, 2017**

Event: Monthly Journal Club Date and Time: 6:30 - 8pm, Wednesday, September 6

Location: V16 Sushi, 3092 16th St, San Francisco, CA 94103

Cost: No cost

Join us for the AWIS Journal Club: a group of scientists who come together monthly to discuss a timely article. This is a great opportunity stay up-to-date on the latest trends in science while making new connections!

Each month a volunteer scientist selects a recent, peer reviewed article that is considered highly important in their field. In the meeting the presenter gives

- A brief overview with relevant background information about the field and why this paper/study is relevant (i.e. what paradigms it is shifting, what policies it impacts)
- A summary of the methods and information in the paper in non-expert terms

Following the overview and summary, we have an open discussion can include:

- Clarifying questions about the science in the paper and its conclusions
- Critiques about the science or ideas for follow-up experiments for deeper insight
- Social/political/scientific implications of the conclusions published

Topics range across biotechnology, materials science, science-based public health, clinical regulations, ecology and evolutionary biology. Anything is fair game. Prior to each meeting, an article is provided to read for those who like to come with set opinions/questions. However, this is NOT required. Feel free to just show up and get a crash course in the subject :)

This month's article:

Photoelectrochemical Behavior of a Molecular Ru-Based Water-Oxidation Catalyst Bound to TiO<sub>2</sub>-Protected Si Photoanodes

The production of solar fuels is a promising approach towards the development of renewable energy sources. The first step in manufacturing solar fuel requires oxidation of water to O<sub>2</sub> (g) and H<sub>2</sub> (g). This paper describes one strategy, taken by leaders in artificial photosynthesis research, towards building a viable device for photocatalytic water oxidation. Come to Journal Club to learn exactly what 'solar water splitting' is, how the process could eventually be used to impact our environment and daily lives, and how the work in this paper takes us closer to a new age of renewable energy sources. Oh yeah, and learn a wee bit of inorganic chemistry along the way :)

*Field: Chemistry, sustainability, chemical engineering, renewable resources, solar energy, artificial photosynthesis*

\*\*\*\*\*

**JLABS, Thursday Morning, Sept. 7, 2017**

Event: Meet with...NCI and NHLBI

Speakers:

Kurt Marek, Ph.D. | Deputy Director, National Heart, Lung, and Blood Institute read bio»

Greg Evans Ph.D. | Supervisory HSA and Team Leader, Cancer Imaging/ Biology/ Control , SBIR Development Center, National Cancer Institute read bio»

Date and Time: Friday September 8th, 10:00AM to 4:00PM | 1-on-1 meetings

\*30 minutes each

Agenda:

Thursday September 7th

10:00AM | Registration and Networking

10:30 AM | Presentation and Q&A

11:45 AM | Networking Lunch

1:00-5:15 PM | One-on-One Meeting\*

\*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due August 17th. Apply Here.

Location: Johnson & Johnson Innovation, JLABS, 329 Oyster Point Blvd, 3rd Floor, South San Francisco, CA

Fees:

#### Presentation

\$25 | General Public

\$35 | Onsite

Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on September 6th (or sold out).

#### One-on-One Meeting

FREE | Application

FREE | Accepted Companies

Apply to meet one-on-one with representatives from NCI and NHLBI Your application will be reviewed and you will be notified of acceptance on Thursday, August 24th 2017. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.

Details and registration at <https://www.eventbrite.com/e/meet-withnci-and-nhlbi-tickets-35582432012?aff=weekly>

#### Event Description

The National Cancer Institute Small Business Innovation Research (NCI SBIR) is returning to the Bay Area. This year they will be joined by representatives from the National Heart, Lung, and Blood Institute(NHLBI), Division of Cardiovascular Sciences. The joint presentation will be held on September 7th with 1-on-1\* meetings, for accepted companies, scheduled on September 7th and 8th.

\*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due by August 18th. Apply Here.

On Thursday, September 7th, Greg Evans, NCI SBIR and Kurt Marek, NHLBI will highlight funding opportunities and other resources for startups in the cancer and cardiovascular sciences.

#### Program Overview:

NCI and NHLBI Present Current and New Funding Opportunities

The representatives will discuss the exciting new non-dilutive targeted funding opportunities in cancer and cardiovascular focused technology development. They will explain the application and review process at the NIH to help small businesses submit stronger applications. The team will discuss key requirements, timelines, important contacts as well as the best practices for successful applications. Additionally, the presentation will touch on the I-Corps at NIH program and other initiatives to facilitate the success of SBIR companies. .

Following the presentation on Thursday afternoon, September 7th and Friday September 8th, the NCI and NHLBI will meet with selected companies for 1-on-1 meetings. To be considered for a one-on-one meeting, please apply here, by August 17th.

Kurt Marek, Ph.D. | Deputy Director, National Institutes of Health/NHLBI Office of Translational Alliances and Coordination

Office of Translational Alliances and Coordination Dr. Marek is the Deputy Director of the Office of Translational Alliances and Coordination (OTAC) at the National Heart, Lung, and Blood Institute (NHLBI). OTAC is charged with developing trans-NHLBI programs to foster the translation of early stage discoveries into commercial products. The Office coordinates the NIH Centers of Accelerated Innovations and the Institute's small business program. Dr. Marek is the Program Director for the NIH Research and Commercialization Hubs program and oversees the Institute's efforts to

support small businesses performing research and development on innovative biomedical products and to facilitate partnerships between small businesses, investors and strategic partners. Dr. Marek has received numerous awards over the course of his government service, and has served as an organizer of and speaker at national conferences.

^ Back to speakers' list ^

Greg Evans Ph.D. | Supervisory HSA and Team Leader, Cancer Imaging/ Biology/ Control , SBIR Development Center, National Cancer Institute

Dr. Greg Evans is a molecular biologist/biochemist by training who has worked at NIH for 26 years. He has 19 years experience as an NIH Program Director managing early-stage, bench-to-bedside (Translation I) research projects. Since June of 2008, Dr. Evans has served as a Team Leader and Program Director within the National Cancer Institute (NCI) SBIR Development Center, an office created in 2007 to centralize management of all NCI SBIR/STTR funding, to increase marketing efforts in the small business and biotechnology investment communities, and to raise the bar for commercialization of cancer-related products and services by small businesses. As a Team Leader and Supervisor, Dr. Evans leads a group of 5 Program Directors responsible for small business projects in the imaging, cancer biology, and behavioral medicine areas. As a Program Director, he is responsible for a technically diverse portfolio that includes projects focused on imaging devices, drug development, diagnostics, basic cancer biology, and population-based cancer prevention.

Prior to coming to the NCI SDC, Dr. Evans worked from 1998-2008 as a Program Director for research on hemoglobin disorders within the Blood Division of the National Heart, Lung, and Blood Institute (NHLBI) at NIH. In that capacity, he managed for five years the Comprehensive Sickle Cell Centers Clinical Trials Consortium, a 20-institution academic collaborative group funded to develop and implement collaborative Phase I-II clinical studies in sickle cell disease. Dr. Evans played a lead role coordinating and facilitating the development of 7 collaborative clinical studies. He also managed a joint NHLBI-Pfizer project for a Phase II/III contract clinical trial of Sildenafil (Viagra) for pulmonary hypertension secondary to sickle cell disease. In that effort, he played a key role in the development of an Independent Research Grant Agreement with Pfizer that covered donation of the study medication and matched placebo, as well as Pfizer's special requirements for adverse event reporting. In addition, while with NHLBI Dr. Evans managed three projects under the NIH RAID (Rapid Access to Intervention Development) program, all of which involved both academic and commercial stakeholders. Lastly, he served on NHLBI-wide programs focused on translational research (e.g. Programs of Excellence in Gene Therapy, 2000-2005; Programs for Genomic Applications, 2000-2008).

Prior to moving to NHLBI to take a research administration position, Dr. Evans was a Senior Staff Fellow from 1995-1998 at the National Human Genome Research Institute at NIH, where he studied and published on gene therapy for the blood clotting disorder Hemophilia A. Before that, he served from 1991-1995 as a American Cancer Society postdoctoral fellow, and an intramural research and training fellow at the NCI, where he studied and published on MDR1-mediated multidrug resistance in cancer.

Dr. Evans received a Ph.D. in Biochemistry in 1991 from the UCLA, and a B.A. in Biochemistry from UC Berkeley in 1982. He is a native of Santa Rosa, California.

\*\*\*\*\*

**MedTech Frontiers, Thursday Evening, Sept. 7, 2017**

Topic: "From the Battlefield to Bedside: Expanding the use of endovascular resuscitation devices to optimize the care of the critically ill and wounded"

Speaker: M. Austin Johnson, MD, PhD, Assistant Professor of Emergency Medicine at UC Davis Medical Center and Co-Founder, 3Ci

Date: Thursday, September 7, 2017

Time: 6:00 - 9:00 pm, presentation begins at 6:45 pm

Location: Triple Ring Technologies, 39655 Eureka Drive, Newark, CA

Cost: The seminar is free, but registration is required for planning purposes

Register at

<https://events.r20.constantcontact.com/register/eventReg?oeidk=a07eehma2yc7f477f29&seq=&c=&ch=>

**Seminar Description**

Advances in endovascular technology over the last 20 years have allowed for small minimally invasive devices to be used during the early care of patients dying from hemorrhage. Although first described in the Korean Conflict, inflating balloon-tipped catheters in blood vessels to block blood flow to control bleeding did not become commonplace until the last 10 years as U.S. Military vascular surgeons cared for wounded soldiers in Iraq and Afghanistan. The vascular surgery technical revolution of the 1990's set the stage for the emerging concept of Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA). REBOA is a trauma resuscitation maneuver in which a balloon catheter to occlude the body's main artery can stop the flow of blood to the abdomen and pelvis thereby decreasing ongoing hemorrhage to stabilize a patient long enough for transfer to surgery.

Although REBOA can save lives, it has serious consequences and can only be used for brief periods of time. Occluding the aorta limits blood flow to the spinal cord, kidneys, and bowels causing profound ischemia which rapid leads to multi-organ failure. These serious side effects have prevented the widespread adoption of REBOA. Therefore, new methods and devices for endovascular bleeding control must be developed so that more patients might benefit from these potentially lifesaving interventions.

While aortic occlusive technologies were first developed for hemorrhage control, the ability to compartmentalize blood flow throughout the body has provided new opportunities for the resuscitation of patients suffering from multiple etiologies of shock. Understanding the tolerable thresholds of ischemia of different vital organs in different shock states while creating new technologies that allow titratable volumes of flow will allow providers to harness the power of endovascular resuscitation for a greater number of patients.

Dr. Austin Johnson and his collaborators have developed novel methods to extend the total duration of aortic occlusion technology. Through their work, new concepts for the resuscitation of critically ill and injured patients have been developed. While some of these new concepts have already been successfully used to save lives, other concepts require the development of advanced technology to fully realize the potential of endovascular resuscitation. Please join us as Dr. Johnson discusses the future of resuscitation, and the historical perspective of one of the most exciting recent technological revolutions in trauma and critical care medicine

**Speaker Bio**

Austin Johnson, MD, PhD is an assistant professor of Emergency Medicine at UC Davis Medical Center and a co-founder of 3Ci, a biomedical device company based in Sacramento. Dr. Johnson is a practicing emergency medicine physician as well as the principal investigator of a DoD-funded laboratory. He has a PhD in neuroscience with an expertise in tissue engineering and electrophysiology. Besides developing novel devices and techniques for endovascular resuscitation, Dr. Johnson has developed biomedical devices to optimize ventilation for critically ill patients as well as novel critical care platforms capable of providing care autonomously in resource and provider constrained settings.

\*\*\*\*\*

## **JLABS, Monday-Tuesday, Sept. 11-12, 2017**

Join the Janssen Human Microbiome Institute, JLABS @ SSF, Stanford Medicine, and Seventure for the 2017 West Coast Microbiome Forum, a 2-day event exploring key aspects of microbiome research. \*\*Note - There is separate registration for each day.

September 11: Bioinformatics for the Microbiome, hosted by Stanford Medicine. Details/Register with Stanford here (Link will redirect you to a non-J&J Innovation website)

September 12: Bugs, Drugs & Beyond: Translational Approaches to the Microbiome, hosted by JHMI and JLABS.

Bugs, Drugs & Beyond: Translational Approaches will explore the ways in which innovators from San Francisco and beyond are harnessing the human microbiome and advancing novel therapeutics, diagnostics and other health products. During this event, we'll hear from entrepreneurs, academics, investors, and biotech and pharma companies about a variety of product development approaches and the organizations pursuing them.

Agenda:

10:00am | Registration

10:15am | The Microbiome: A New Paradigm for Health Solutions

10:30am | Insights from the Front Lines of Microbiome Innovation

11:00am | QuickFire Challenge, Part I

12:00pm | Lunch and Gallery Walk

1:15pm | Panel Discussion: From Validation to Regulation: Breaking Down Barriers to Microbiome Progress

2:15pm | QuickFire Challenge, Part II

3:15pm | Networking Reception and QuickFire Challenge Winner Announced

4:30pm | Program Close

Location: Quadrus Conference Center & Catering, 2400 Sand Hill Rd., Menlo Park, CA 94025

Registration at <https://www.eventbrite.com/e/bugs-drugs-beyond-translational-approaches-to-the-microbiome-tickets-34552212598?aff=weekly>

Interactive sessions will highlight:

Challenges in advancing to market, from IP protection to commercialization

Potential solutions and pathways currently being pursued across the field

Opportunities for collaboration

The Bugs, Drugs & Beyond QuickFire Challenge:

Are you a game-changing early-stage microbiome company? The Bugs, Drugs & Beyond QuickFire Challenge is officially open! We encourage innovators with promising ideas or research with the potential to impact patients to apply now. The winner will be awarded a customized package of support from the JHMI and JLABS,

and will be announced at the event of the event on September 12. Applications for the Bugs, Drugs, & Beyond QuickFire Challenge will remain open until July 14, 2017. Apply online today!

**Speakers:**

Miguel Barbosa | Chief Scientific Officer -Microbiome, Assembly Biosciences ; Colleen Cutcliffe, CEO, Whole Biome Inc.; Dirk Gevers. Global Head, Janssen Human Microbiome Institute, Janssen R&D Denise Kelly, Investment Advisor, Seventure; Justin Sonnenburg, Principal Investigator, Stanford University  
[Moderator] Stephanie Roberston, Sr Director of Consumer Science Innovation, Johnson & Johnson Innovation

Location: Quadrus Conference Center, Menlo Park, CA 94025

**Fees:**

\$40 | General Public

\$20 | Student/Academic

\$45 | At the door

Details and registration at <https://www.eventbrite.com/e/bugs-drugs-beyond-translational-approaches-to-the-microbiome-tickets-34552212598?aff=weekly>

**Speakers' Biographies:**

Miguel Barbosa, Chief Scientific Officer -Microbiome, Assembly Biosciences  
Dr. Barbosa has more than two decades of experience leading drug discovery and development programs at major pharmaceutical and biotechnology companies. Until 2015, Dr. Barbosa was Global Head and Vice President of Immunology Research and External Innovation at Janssen Research & Development, where he oversaw immunology R&D and new program initiatives, including establishing the foundation for, and then leading, Johnson & Johnson's new microbiome enterprise. Earlier in his career, Dr. Barbosa held positions of increasing responsibility managing new drug R&D programs at prominent biopharmaceutical firms, including Centocor, Signal Pharmaceuticals, TRL USA, Chugai Biopharma and Mirna Therapeutics. Dr. Barbosa received a BS degree from the University of California, Davis and a PhD from the University of California, Los Angeles. He completed a post-doctoral fellowship at the National Cancer Institute..

Joseph Petrosino Colleen Cutcliffe, CEO and Co-founder, Whole Biome, Inc.  
Colleen Cutcliffe is the CEO and Co-Founder of Whole Biome Inc. She has over 15 years of experience leading and managing biology teams in academia, pharmaceuticals and biotechnology. Prior to starting Whole Biome, Colleen was the Senior Manager of Biology at Pacific Biosciences and a Scientist at Elan Pharmaceuticals. Colleen received her Ph.D. in Biochemistry and Molecular Biology from Johns Hopkins University and her B.A. in Biochemistry from Wellesley College..  
^ Back to Speakers' list ^

Stephanie Robertson Dirk Gevers, Global Head, Janssen Human Microbiome Institute, Janssen R&D

Dirk Gevers, Ph.D., is Global Head of the Janssen Human Microbiome Institute (JHMI), where he leads efforts to expand scientific understanding and capabilities in this emerging area of science. Previously, Dirk was Senior Group Leader of Microbial Systems and Communities at the Broad Institute of MIT and Harvard, serving as a scientific liaison among various organizational components, including the institute's data generation platforms and both clinical and analytical collaborators on microbiome-related projects. Dirk's research included the characterization of the

microbial imbalance associated with diseases such as Crohn's disease, type 1 diabetes and colorectal cancer. He was also involved with the National Institutes of Health Human Microbiome Project, holding a leading role in the Data Analysis Working Group. Dirk received his Ph.D. in biochemistry from Ghent University (UGent), Belgium, and completed postdoctoral training at UGent and the Massachusetts Institute of Technology in bioinformatics, comparative and evolutionary genome analysis and microbial ecology.

^ Back to Speakers' list ^

Justin Sonnenburg Denise Kelly, Investment Advisor, Seventure

Denise joined Seventure in September 2015 as an investment Advisor to the Life Sciences Team for microbiome field. Her focus is in Human Microbiome Research and her time is dedicated to coverage of scientific and academic community on behalf of Seventure, and to prospect new investment opportunities in the specific field of microbiome. Denise is currently based in Aberdeen, Scotland. Prior to joining Seventure, Denise was Head of her Research team at the World-renowned Rowett Institute, University of Aberdeen, where she acquired over 20 years experience in gut microbiology and immunology. She was the (former) Founder Director, CEO and CSO of GT Biologics Ltd, one of the first translational spinouts, developing Innovative Microbiome-based Therapies.

Denise Kelly Justin Sonnenburg, Principal Investigator, Stanford University

Justin Sonnenburg conducted his Ph.D. in Biomedical Sciences at the University of California, San Diego. His graduate studies in the laboratory of Ajit Varki focused on the biological roles of glycosylation, performing comparative studies on sialic acids and their receptors in humans and great apes, to shed light on the molecular evolutionary history of humans. In 2003, Justin moved to Washington University in Saint Louis, Missouri to join the laboratory of Jeffrey Gordon, where he applied his background in glycobiology to study host-microbial interactions within the gastrointestinal tract. During his post-doc, Justin investigated model microbial communities living within the gut of gnotobiotic mice to define the basic principles that govern interactions within the microbiota and between the microbiota and the host. In 2008, Justin moved back to California and is currently Assistant Professor in the Department of Microbiology and Immunology at the Stanford University School of Medicine. In 2009 Justin was the recipient of an NIH Director's New Innovator Award. In 2011 he received the Burroughs Wellcome Fund Investigators in Pathogenesis of Infectious Disease Award. He and Erica Sonnenburg, PhD, are the authors of the forthcoming book *The Good Gut: Taking Control of Your Weight, Your Mood, and Your Long Term Health*.

The Sonnenburg lab is currently focused on understanding basic principles that govern interactions within the intestinal microbiota and between the microbiota and the host. To pursue these aims, his lab colonizes germ-free (gnotobiotic) mice with simplified, model microbial communities, applies systems approaches (e.g. functional genomics), and uses genetic tools for the host and microbes to gain mechanistic insight into emergent properties of the host-microbial super-organism.

^ Back to Speakers' list ^

Migeul Barbosa Stephanie Roberston, Sr Director of Consumer Science Innovation, Johnson & Johnson Innovation

Stephanie is part of the New Ventures Team at J&J Innovation. As part of her role at J&J Innovation, she works closely with the Janssen Human Microbiome Institute and with J&J Consumer Emerging Sciences to create collaborations with academic experts and biotech companies with a goal of accelerating the translation of microbiome research into breakthrough solutions that promote health. Previously Stephanie was at the University of California, San Francisco UCSF where she helped to establish and grow translational efforts on campus including her role as Program Director for the Sandler Center for Drug Discovery, and for the Grand Multiple Myeloma Translational Initiative. She later took on the role of Director, Strategic Alliances where she led business development and alliance management activities for the campus. Prior to joining UCSF, Stephanie worked for over a decade at Exelixis, Inc, where she held diverse leadership roles including leading a computational biology team and acting as scientific project leader for numerous drug discovery programs in cancer, cardiovascular disease and metabolism as well as managing early oncology clinical programs and alliances for several programmatic collaborations with large pharma.

Stephanie earned an undergraduate degree in chemistry (Honors) at the University of Michigan, Ann Arbor, and a Ph.D. in chemistry at the University of California, Berkeley.

\*\*\*\*\*

**Bio2Device Group, Tuesday Evening, Sept. 12, 2017**

Topic: "Behavioral Design for Wearables and Health-IT: Pitfalls and Promises"

Speaker: Sunil Maulik, Innovator, Educator, Entrepreneur

Date and Time: Tuesday, Sept. 12, 2017, 6:00 pm

Location: Wilson Sonsini Goodrich & Rosati - 650 Page Mill Road, Palo Alto

Cost:

\$6 - Students/In-transition - Members only

\$11 - Early-bird Registration - Members only

\$20 - Late Registration and Non-Members

\$25 - Walk-ins

Register at Bio2Device Group website [www.Bio2DeviceGroup.org](http://www.Bio2DeviceGroup.org)

**Speaker Bio**

Sunil Maulik has over twenty-five years of experience in Silicon Valley. He teaches workshops on product design for long-term behavior change in the technology and healthcare industries. He has given keynote speeches at Triple Ring Technologies, Product Realization Group, Genentech, Perkins-Coie, Alterra, Roche, Health2.0 and numerous other organizations. He has been a mentor and advisor to over 50 startups. Sunil helped start five companies (two IPOs (OXMOL; TRPS), two acquisitions (Moneta, 500Friends), one spectacular failure (Pangea Systems!) He co-founded and ran GeneEd, the first e-learning company focused on long-term behavior change for providers and patients. (Acquired by InVentiv Health in 2008.) Sunil is an advisor at The Innovation Center Denmark, a Danish government-funded design and innovation agency with offices in eight countries. He has guest-lectured at the Stanford d-school, U.C. Berkeley, and at the University of Amsterdam (THNQ.) Sunil has held management positions at Pangea Systems, Tripos (NASDAQ:TRPS), Hoffmann-La Roche (NYSE: ROCHE), Oxford Molecular (LSE: OXMOL), and IntelliGenetics. Sunil's thesis research on mathematical methods for 3-D image reconstruction of biological assemblies was published on the cover of the scientific journal Nature. His book "Molecular Biotechnology" (J. Wiley & Sons) sold over 4000 copies and was used in four university courses. He holds patents in fields as diverse as gene sequence pattern-matching, e-learning and e-mail analytics. Sunil worked with the Nobel-prize winners Maurice Wilkins

and Aaron Klug as an undergraduate, and Sir Tom Blundell and Donald Caspar as a graduate student. He holds degrees in Physics (B.Sc.), Biology (B.Sc.), X-ray Crystallography (M.Sc.) and Biophysics (Ph.D.) After graduate school, he participated in AI research at Bionet™ with Drs. Peter Friedland, Doug Brutlag, Russ Altman and Ed Feigenbaum of Stanford.

Sunil participates in several non-profit ventures dedicated to health and wellness in sustainable communities, including the Pacific AIDS Education Center and Project Ahimsa. He is enthralled by the opportunity to help extend wellness across the globe by bringing the power of informatics to everyday users.

\*\*\*\*\*

**WIB-San Francisco YWIB, Tuesday Evening, Sept. 12, 2017**

Topic: "STEM CELLS... All the cool girls are discovering them!"

Date and Time: Tuesday, September 12, 2017, 4:00 p.m. - 7:00 p.m. PST

Program

4:00 p.m. – 4:30 p.m.

Check In and Welcome

4:30 p.m. – 5:15 p.m.

What are Stem Cells?

5:15 p.m. – 6:00 p.m.

Professionals in Science Panel

6:00 p.m. – 7:00 p.m.

Women in Science Activity and Dinner

Location: California Institute for Regenerative Medicine, 1999 Harrison Street, Suite 1650 Oakland, CA, 94612

Parking Information

The Lake Merritt Plaza parking garage is open to the public Monday through Friday from 5:00 a.m. - 7:00 p.m.

Public Transit Information

Easily accessible from the 19th St. Oakland BART station

Pricing Information

Members: Free

Non-Members: Free

Details and registration at <http://womeninbio.org/eventdetails.aspx?EventId=31771>

Registration Deadline

September 7, 2017

Maximum Capacity

40

Event Description:

Come join WIB-San Francisco Bay Area Young Women In Bio and California's Stem Cell Agency on September 12 to learn what stem cells are, ask questions of science professionals, and become a spokeswoman for girls in science!

Please read the YWIB permission forms located here.

YWIB Participant Age Range

9th through 12th grade

Walk-Ins Accepted?

Walk-ins and guests are not accepted – be sure to register early

\*\*\*\*\*

**QB3 Rosenman Institute D-Series, Tuesday Evening, Sept. 12, 2017**

Event: An Interview with Justin Klein of New Enterprise Associates  
Date and Time: Tue, September 12, 2017, 5:00 PM – 7:00 PM PDT  
Location: Byers Hall, Room 212, 1700 4th Street, UCSF Mission Bay, San Francisco, CA 94158  
Admission: Free for QB3 and UC Affiliates; \$10 for general admission  
Refunds up to 1 day before event  
Details and registration at [https://www.eventbrite.com/e/an-interview-with-justin-klein-of-new-enterprise-associates-tickets-37067803799?mc\\_cid=5316113df7&mc\\_eid=cb4c38a44a](https://www.eventbrite.com/e/an-interview-with-justin-klein-of-new-enterprise-associates-tickets-37067803799?mc_cid=5316113df7&mc_eid=cb4c38a44a)

**Event Description**

Join us Tuesday, September 12, when venture capitalist Justin Klein of New Enterprise Associates (NEA) will give us an inside view on the current state of healthcare investing. Christine Winoto, director of the Rosenman Institute, will interview Justin.

**Speaker Bio**

*Justin Klein* joined NEA in 2006 and is a Partner on the healthcare team. He focuses on medical device, healthcare technology, and biopharmaceutical company investments. He serves as a director of Advanced Cardiac Therapeutics, Cartiva, ChromaCode, FIRE1, Intact Vascular, Personal Genome Diagnostics, PhaseBio Pharmaceuticals, Relevant Medsystems, Senseonics (NYSE: SENS), VertiFlex, Vesper Medical, and VytronUS. Justin’s past board memberships and investments include CV Ingenuity (acquired by Covidien), Nevro (NYSE: NVRO), Topera (acquired by Abbott), TriVascular (NASDAQ: TRIV), and Ulthera (acquired by Merz). He is also a member of the advisory boards for the National Venture Capital Association’s Medical Industry Group and its Medical Innovation and Competitiveness Coalition (MedIC), as well as a member of AdvaMed's Business Development Committee.

Prior to NEA, Justin worked for the Duke University Health System—reporting directly to the hospital CEO on health system strategy, finance and clinical service unit operations—as Duke built one of the nation's first and largest healthcare integrated delivery systems. Justin concurrently earned his MD from the Duke University School of Medicine and his JD from Harvard Law School. He has also served as a member of the Board of Trustees of Duke University, where he earned his AB in Economics and his BS in Biological Anthropology and Anatomy.

\*\*\*\*\*

**EMBS, Wednesday Evening, Sept. 20, 2017**

Topic: kV X-ray Digital Tomosynthesis Image Tracking of Respiratory Motion During The Delivery of MV Radiotherapy Treatment of Cancer.  
Speaker: Larry Partain, Director of Clinical Research, TeleSecurity Sciences, Silicon Valley Operations, Los Altos, CA  
Date and Time: Wednesday, September 20, 2017, 7:30 PM  
Location: Room M-114 of the Alway Bldg., Stanford University School of Medicine (see campus map at link below).

Optional dinner location: Stanford Hospital cafeteria, 6:15 PM (no host, no reservations, self-serve)

The Stanford campus map is at: <https://campus-map.stanford.edu/>  
Parking is usually free after 5 PM at Roth Way Garage, which is at the corner of Roth Way and Campus Drive on the map. The Stanford Hospital Cafeteria is across Campus Drive from Roth Way Garage and near the Emergency entrance. The meeting is in Room M-114 of the Alway Building, which is also across Campus Drive from Roth Way Garage, and Room M114 is accessible from outside the Alway Building.

#### Topic Description

External beam radiotherapy, widely applied in the treatment of cancer, directs a constantly re-shaped beam of gamma rays (i.e. MeV photons) from outside a patient to non-surgically enter the patient's body to destroy a malignant lesion, as this focused treatment beam circles the patient's body, for a lesion positioned near the center of rotation. A priority early application is treatment of lung cancer in free breathing patients where the cancer lesion can easily move up and down a cm or more during respiratory cycles (every 4 to 6 sec.) for continuous treatments that can typically last a minute or more. Since real time viewing of respiratory motion of objects has not usually been available during radiotherapy, the standard protocol delivers this lethal dose over the total volume traversed by the lesion during multiple breathing cycles. Unfortunately this directly kills about 2% of the patients treated and seriously injures a larger fraction due to the radiation damage to healthy surrounding lung tissues, the heart, the spinal cord and other "organs at risk" including the ribs. The success of this x-ray tomosynthesis tracking technology has the potential to significantly reduce the magnitude of such collateral damage.

\*\*\*\*\*

#### **PBSS, Wednesday Seminar Luncheon, Sept. 13, 2017**

Topic: "Unique Clinical Pharmacology & Biopharmaceutics Properties of Vyxeos: Development of a Nano-scale Fixed-ratio Cytarabine/Daunorubicin Liposomal Formulation for Acute Myeloid Leukemia"

Speaker: Jackie Gibbons, Ph.D, Jazz Pharmaceuticals

Organizer: Tracy Chen

Date and Time: 9/13/2017, 11:00-13:30

Registration deadline: 9/12/2017 Registration fee (USD): ;

Location: SF Bay Area: Foster City Crowne Plaza

Registration: <http://www.PBSS.org>

#### Speaker Bio

Jackie Gibbons, Ph.D, is currently Head of Clinical Pharmacology at Jazz Pharmaceuticals, an international biopharmaceutical company with marketed products and development programs in the areas of sleep and hematology/oncology. She earned a BS in Biology from UC Berkeley and a PhD in Toxicology at Cornell University, where she studied cytochrome P-450 enzyme systems. Jackie has worked in the field of drug metabolism and pharmacokinetics for more than 25 years, and her former companies include Chiron, Bayer, and Medivation. She will be speaking on Vyxeos, a nano-scale liposomal formulation of a fixed 5:1 molar ratio of the antineoplastic agents, cytarabine and daunorubicin. In 2016, FDA granted breakthrough therapy designation for the use of Vyxeos in treating of acute myeloid leukemia, and Jazz submitted an NDA in March 2017. Jackie led the clinical pharmacology and biopharmaceutics portions of the NDA and will describe how the unique

biopharmaceutics properties of Vyxeos affect its tissue distribution, pharmacokinetics, and exposure-response.

\*\*\*\*\*

**QB3 Seminars for Life Science Entrepreneurs, Tuesday Mid-Day, Sept. 19, 2017**

Topic: "CSO: Point of the Innovation Spear"

Speaker: Zach Serber, Chief Science Officer and Vice President of Development, Zymerge

Date and Time: Tue, September 19, 2017, 12:00 PM – 1:00 PM PDT

Location: Room 160, Helen Diller Bldg., 1450 3rd Street, San Francisco, CA 94158

Cost: Free for QB3 and UC Affiliates; \$10 for regular admission

Registration and details at <https://www.eventbrite.com/e/zach-serber-zymergen-cso-point-of-the-innovation-spear-tickets-37071407578?aff=erelpanelorg#tickets>

Topic Description

Maintaining a competitive edge in technology is key to startup success. The chief technology or science officer keeps that edge sharp by conceiving and developing new innovations, often managing a team of scientists and engineers. So what's it like to have that responsibility? Join us on September 19 to find out. We'll hear from Zach Serber, CSO at Zymergen, which was recently profiled by Science for its application of robotics and machine learning to the refinement of industrial microbes.

Speaker Bio

*Dr. Zach Serber* is a scientist and entrepreneur devoted to using bioengineering to drive the next industrial revolution. In 2013, Dr. Serber co-founded Zymergen, a technology company unlocking the power of biology by combining biology with technology such as robotics and machine learning. Today, he is the company's Chief Science Officer and Vice President of Development overseeing scientific direction, new products, and development teams.

Dr. Serber was previously the Director of Biology at Amyris where he worked on manufacturing bio-derived transportation fuels, on lowering the cost of the antimalarial drug, Artemisinin, and on developing advanced tools for engineering biology. He has been PI on multiple DARPA contracts including an \$8M contract devoted to improving the genome engineering cycle and, currently, a \$31M contract to develop 360 microbes, each producing a novel molecule with the potential to generate innovative polymers and materials.

Dr. Serber has 17 peer-reviewed publications in journals such as Cell and Science, multiple patents, and has worked as a research fellow at Stanford University Medical School. He has a PhD in Biophysics from University of California San Francisco, a MSc in Neuroscience from the University of Edinburgh, and a BA from Columbia University.

Zach lives with his wife, two children, and dog on a sailboat in Sausalito, CA.

\*\*\*\*\*

**EMBS, Wednesday Evening, Sept. 20, 2017**

Topic: kV X-ray Digital Tomosynthesis Image Tracking of Respiratory Motion During The Delivery of MV Radiotherapy Treatment of Cancer.

Speaker: Larry Partain, Director of Clinical Research, TeleSecurity Sciences, Silicon Valley Operations, Los Altos, CA  
Date and Time: Wednesday, September 20, 2017, 7:30 PM  
Location: Room M-114 of the Alway Bldg., Stanford University School of Medicine (see campus map at link below).

Optional dinner location: Stanford Hospital cafeteria, 6:15 PM (no host, no reservations, self-serve)

The Stanford campus map is at: <https://campus-map.stanford.edu/>  
Parking is usually free after 5 PM at Roth Way Garage, which is at the corner of Roth Way and Campus Drive on the map. The Stanford Hospital Cafeteria is across Campus Drive from Roth Way Garage and near the Emergency entrance. The meeting is in Room M-114 of the Alway Building, which is also across Campus Drive from Roth Way Garage, and Room M114 is accessible from outside the Alway Building.

#### Topic Description

External beam radiotherapy, widely applied in the treatment of cancer, directs a constantly re-shaped beam of gamma rays (i.e. MeV photons) from outside a patient to non-surgically enter the patient's body to destroy a malignant lesion, as this focused treatment beam circles the patient's body, for a lesion positioned near the center of rotation. A priority early application is treatment of lung cancer in free breathing patients where the cancer lesion can easily move up and down a cm or more during respiratory cycles (every 4 to 6 sec.) for continuous treatments that can typically last a minute or more. Since real time viewing of respiratory motion of objects has not usually been available during radiotherapy, the standard protocol delivers this lethal dose over the total volume traversed by the lesion during multiple breathing cycles. Unfortunately this directly kills about 2% of the patients treated and seriously injures a larger fraction due to the radiation damage to healthy surrounding lung tissues, the heart, the spinal cord and other "organs at risk" including the ribs. The success of this x-ray tomosynthesis tracking technology has the potential to significantly reduce the magnitude of such collateral damage.

\*\*\*\*\*

#### **JLABS, Thursday Afternoon, Sept. 21, 2017**

Topic: "From Chemical to Drug: The Path to a Small Molecule IND"

#### Speakers

Anders Brunmark | Sr Director, External Innovation, Discovery Sciences, Janssen R&D

Mark Krook | Sr. Scientific Director, Portfolio Management, Janssen R&D

Sandra Snook | Sr. Director, Preclinical Development & Safety, Janssen R&D

Jan de Jong | Scientific Director, Clinical Pharmacology, Janssen R&D

Katherine Tsokas | Regulatory Head, Regenerative Medicine & Advanced Therapy, Janssen R&D

Date and Time: Thursday, September 21, 2017, 12:30- 5:00 pm

#### Agenda

12:30 PM | Registration, Lunch, and Networking

1:00 PM | Janssen Research & Development - your partner of choice

1:30 PM | Preclinical Development Strategies

- Pharmacokinetics, distribution and metabolism in Discovery and Early Development
- picking the right molecule
- Preclinical toxicology evaluations before and during GLP toxicology
- Considerations for typical FIH Program
- Case study

#### 2:15 PM | Chemistry, Manufacturing and Controls Strategies

- Optimizing manufacture of your API
- Drug product formulations for FIH

#### 3:00 PM | Break

#### 3:15 PM | Clinical Pharmacology

- Designing FIH trials
- Understanding PK/PD
- Biomarkers of safety and efficacy
- Case study

#### 4:00 PM | Regulatory - Satisfy Statutory Legal Requirements for Testing in Humans

- Regulatory Strategy
- Data requirements: CMC, safety, clinical plan
- eCTD
- Pre-IND meetings
- Case study

#### 4:45 PM | Discussion and Q&A

#### 5:00 PM | Program Close

Location: Byers Hall Auditorium, University California San Francisco, 600 16th St., San Francisco, CA

#### Fees:

- \$35 | General public
- Free | UCI students/staff
- \$20 | Other student/academic
- \$35 | At the door

Register at <https://www.eventbrite.com/e/from-chemical-to-drug-the-path-to-a-small-molecule-ind-tickets-34888361027?aff=blast>

#### Program overview

#### Topic Description

Do you have a solid plan to achieve IND acceptance? Filing an Investigational New Drug (IND) application might be the next step in advancing your company's early-stage drug development program. Johnson & Johnson Innovation, JLABS and Janssen Discovery Sciences invite you to an in-depth look into the process of filing an IND.

Whether your goal is to develop a pipeline through commercial launch or partner as early as possible, submitting an IND is a critical early milestone for every biotech company. With big Pharma and VC firms competing for the most promising compounds, startups are expected to demonstrate a clear blueprint for IND approval, and we want you to be ready.

Join us for a series of short presentations exploring the basic requirements and considerations necessary to achieve a successful small molecule IND submission.

The presentations will highlight the following:

Janssen Research & Development - a brief overview

Preclinical Development strategies for pharmacokinetics, drug metabolism and toxicology

Key CMC strategies to balance cost, time and quality risks

Designing First-in-Human trials to highlight the qualities of your molecule

Regulatory strategy, IND requirements, and Pre-IND meetings

Speakers Bios

**Anders Brunmark, Ph.D. | External Innovation, Discovery Sciences, Janssen R&D**

Anders Brunmark obtained his undergraduate in chemistry at University of Lund and completed his PhD on quinones and free radical biochemistry at University of Linköping, Sweden. He held a faculty position at this University between 1988 and 1992. He did postdoctoral work on immune recognition at the Department of Immunology at The Scripps Research Institute in La Jolla, CA between 1990 and 1994. Anders Brunmark joined J&J's Pharmaceutical R&D organization in 1994 as group leader for protein expression and held a group leader position in Immunology Discovery 1999-2004. In 2004 Anders established an enabling technology team at the La Jolla, California R&D site, comprising DMPK, Pharm Sci/formulations, Genomics, Compound Logistics, and High Throughput Screening functions. In 2012 he took a job as Scientific Director in Integrated Systems Biology. Since 2014 he is Director in External Innovation in Janssen R&D Discovery Sciences with primary responsibility for Western US and Canada. He is an author on 48 papers, 3 book chapters, and inventor on 5 patents. Anders Brunmark's research interests include development and application of new techniques for studying disease mechanisms and drug action both in vitro and in vivo.

**Jan de Jong, Ph.D. | Scientific Director, Clinical Pharmacology, Janssen R&D**

Jan has over 20 years experience in drug development, with a focus on small molecule pharmacokinetics and metabolism. He is currently a Clinical Pharmacology Leader in the Global Clinical Pharmacology department. He holds a master's degree in Pharmacochemistry from the Vrije Universiteit (VU) Amsterdam, the Netherlands, and a doctorate from the same university. Following a temporary Assistant Professorship at the VU, Jan joined the Drug Metabolism & Kinetics department at Organon, the Netherlands. He started at Janssen R&D in Belgium in 2000 as Head of Bioanalysis, and later relocated to the US where he joined the San Diego, CA site and became a preclinical project lead. He transitioned to clinical development to become the ClinPharm Oncology lead for ibrutinib, a first-in-class BTK inhibitor jointly developed and marketed with Pharmacyclics. He has worked on IND packages for several early development projects across various therapeutic areas.

**Mark Krook, Ph.D. | Head, Global Portfolio Management - Small Molecules, Janssen R&D**

Mark has over 30 years of drug development experience in the pharmaceutical industry. He began his career at The Upjohn Company (eventually becoming Pfizer) as a process chemist working on API process development for clinical and commercial needs, eventually moving into the leadership of global, multi-site chemical process R&D organizations with responsibilities for both laboratory and pilot plant facilities.

From there he transitioned to portfolio management, providing broad technical, strategic and governance oversight for cross-functional CMC activities within a diversified portfolio of development projects.

Mark joined Janssen in 2007 as the leader of the ChemPharm API Development group in the US. In 2010, he moved into the PDMS Portfolio Management function where he is currently leading a group of CMC Leaders with responsibility for CMC activities across the entire small molecule development spectrum (pre-clinical to life cycle management).

He earned a B.A. in Chemistry from the College of St. Thomas (now University of St. Thomas) and completed a Ph.D. in Organic Chemistry from the University of Notre Dame

**Katherine Tsokas, J.D. | Regulatory Head of Regenerative Medicine & Advanced Therapy, Janssen R&D Director Regenerative Medicine & Advanced Therapy Network, Johnson & Johnson**

Katherine has 26 years of progressive global regulatory experience in small and large sized Pharma companies. She has worked on products at various stages of development, from early through to filing, approval and commercialization. Currently, her responsibilities include providing strategic regulatory oversight to advanced therapy projects in several therapeutic areas by ensuring regulatory strategies contribute to and support the development plans for the products and that all opportunities for collaboration internally and externally are utilized. Further, through the RMAT Network, Katherine leads J&J cross-sector efforts to enhance awareness and connectivity for the development of processes that enable assessing, partnering, and developing safe and effective advanced therapies globally. In addition, she represents Global Regulatory Affairs on the J&J First in Human Committee. Katherine received her Bachelor of Science Biology from Temple University, Juris Doctorate from Widener University Law School, and is admitted to the practice of law in Pennsylvania and New Jersey.

**Sandra Snook | Sr. Director, Preclinical Development & Safety, Janssen R&D**

Sandra has been supporting the preclinical development of small molecules for 25 years. She is a DVM and board certified Veterinary Pathologist and after a stint leading an academic research group at The University of Chicago, she moved to GD Searle/Pharmacia where she worked for 11 years supporting projects from late discovery through full development. In 2003 she took on the mission to form a nascent Preclinical Development & Safety group for Janssen's La Jolla site. During her career, Sandra has worked across platforms including synthetic peptides, and small and large molecule pharmaceuticals. She has worked across therapeutic areas including infectious diseases, metabolic and cardiovascular diseases, immunology, neuroscience and oncology. Additionally, she has lead staff supporting toxicology and DMPK project support as well as laboratory animal medicine, investigative toxicology and molecular pathology. She and her team have extensive experience supporting innovative compound development from lead optimization through global registration; including managing the preclinical portion of external alliances and partnerships. Her team is frequently called upon to participate in critical due diligence reviews of potential licenses and acquisitions. For the last few years Sandra has also lead the Janssen Imbruvica preclinical development team 9a partnership with Pharmacyclics), one of the first drugs to successfully navigate the Breakthrough Drug designation at the FDA. Sandra received her AB degree from The University of Chicago, a DVM from Iowa State University and served as a post-doctoral fellow in

Comparative Pathology at Harvard University. She served on the faculty of The University of Chicago where she had independent research funding (NIDA) and ran a comparative pathology diagnostic laboratory supporting the LAMS organization in addition to the Lincoln Park Zoo and Shedd Aquarium. Over the years Sandra has been active in both the ACVP and STP. She is an author on 26 papers and 33 posters/presentations.

\*\*\*\*\*

**QB3 SBIR Workshop, Starting Tuesday, Sept. 26, 2017**

Classes offered at UCSF

UCSF: Six sessions, on Tuesdays. Starts Sept. 26, last one Dec. 19  
Location: 212 Byers Hall, UCSF Mission Bay. <http://qb3.us5.list-manage.com/track/click?u=61b2598b3587bfbe0c0972994&id=9f2fca1ac4&e=cb4c38a44a>

**Workshop Description**

For entrepreneurs looking for non-dilutive federal funding to get life science startups off the ground. Small Business Innovation Research (SBIR) grants from US federal agencies can provide up to \$250k (Phase I) or \$1M (Phase II) for startup R&D. But applying can be a complex, frustrating affair if you are not ready for it. We get you ready. Our instructors walk you through your NSF or NIH SBIR grant application to ensure you complete everything properly and submit by the December NSF or January NIH deadlines.

Did you know that entrepreneurs applying through the QB3 workshop are 3x more likely than the nationwide average to get funded?

See the individual registration pages for details.  
Faculty includes:

**Shauna Farr-Jones**  
Grant Writer,  
UCSF/QB3  
[Shauna's LinkedIn profile](#)

**Ioana Aanei**  
Entrepreneurship  
Program Manager,  
QB3

\*\*\*\*\*

**JLABS, Thursday Morning, Sept. 28, 2017**

Topic: "The Race to Market: Building an Efficient Discovery Engine"

Speakers: David Malwitz | Manager, Bioresearch Quality & Compliance, Janssen R&D;  
Lynn Young | Sr. Research Manager, Alliance Business & Portfolio Managements, Janssen R&D;  
Jackie Benson | VP Immunology SCI Innocation, Research Admin, Johnson & Johnson Innovation

Date and Time: Thursday, September 28, 2017 from 8:30 AM to 11:15 AM (PDT)

Agenda:

8:30 AM | Registration and Networking Breakfast

9:00 AM | A roadmap for bringing a drug to market

Drug discovery process

Internal and external stakeholders

Opportunities and challenges

9:15 AM | Dilemmas in discovery - a workshop

An interactive session focusing on potential data handling dilemmas and their associated risks

10:00 AM | Discovery data integrity – a quality approach for Janssen R&D

Sponsorship and support

Training approach

Risk-based monitoring

Phase appropriate solutions

11:00 AM | Discussion and Q&A

11:15AM | Program Close

Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California

Fees:

\$25 | General Public

\$15 | Student/Academic

\$45 | At the door

Details and registration at <https://www.eventbrite.com/e/the-race-to-market-building-an-efficient-di...>

Topic Description

Are you confident in the integrity of your data? Every day, hundreds of scientists are forming the basis of drug discovery. Laboratory data forms the building blocks of the scientific work, and its quality is paramount to crucial business decisions and long term success. Take an in-depth look into potential quality risks and inefficiencies in research and explore measures to improve data quality in the drug discovery processes. Johnson & Johnson Innovation, JLABS (JLABS) and Janssen R&D invite you to an interactive workshop where attendees will work in groups to think about data handling dilemmas and their possible risks..

[This is an interactive workshop including small working groups during the day, therefore space is limited]

Presentations will cover the following topics:

A roadmap for bringing a drug to market

Dilemmas in discovery – a workshop

Reproducibility in research

A quality approach within Janssen R&D

Speaker Bios

David Malwitz | Manager, Bioresearch Quality & Compliance, Janssen R&D

David is responsible for the planning and execution of external strategy in the Non-regulated QA domain of Bioresearch Quality & Compliance. This includes implementing key systems and processes needed to establish a risk-based audit program, operationalizing strategic quality and compliance capabilities, and recruiting the right team and network

across global R&D sites to enable a successful portfolio. In addition, David supports the internal quality maintenance program by leading internal and external assessments across multiple therapeutic areas and has led compliance integration efforts to ensure the successful alignment of acquired assets into the Janssen R&D organization. David began his career as a research scientist at Wyeth Research and Amgen. He has a M.S. in Organic Chemistry from Wright State University and B.S. in Chemistry from Cedarville University.

Lynn Young | Sr. Research Manager, Alliance Business & Portfolio Managements; Janssen R&D

Lynn enables the "business of science" for Discovery Immunology team at Janssen Research & Development. Her focus areas include driving the end-to-end contracts process, ensuring Healthcare Compliance for contracts, monitoring records management and promoting Discovery Data Integrity (DDI) practices. Lynn is a protein biochemist and began her career in the pharmaceutical industry at Tanabe Research Laboratories USA focusing on integrin targets. From there she moved to the RW Johnson Pharmaceutical Research Institute to support drug discovery in the Virology, Infectious Diseases and later the Immunology departments. In 2010, she transitioned to a strategy and operations team supporting the business needs within Research Immunology. Lynn has a M.S. in Biology from the University of California at Irvine and a B.A. in Biochemistry and Cell Biology from University of California at San Diego.

Jackie Benson | VP IMMUNOLOGY SCI INNOVATION, Research Admin Johnson & Johnson Innovation

Jackie is responsible for creating and implementing an external innovation plan focused on developing an industry-leading portfolio of Immunology Therapeutic Area investment opportunities on the West Coast. This work will help solidify Janssen as the partner of choice in a highly competitive landscape, and identify and deliver the best opportunities for value-generating collaborations supporting our Immunology scientific strategy.

In her previous role, Jackie launched and led the Estrela Venture within the Janssen Incubator, advancing innovative treatments for systemic lupus erythematosus (SLE). Jackie led the Estrela Venture to a number of key milestones, including the declaration of two new molecular entities, one of which recently achieved first patient dosed in SLE patients.

Jackie joined the Janssen Pharmaceutical Companies of Johnson & Johnson as a Senior Research Scientist in 2001, playing an instrumental role in the research and discovery of several flagship programs, including STELARA® (ustekinumab), for which she earned a Johnson Medal, and guselkumab. She received her B.S. in Biology from The Ohio State University, followed by her Ph.D. in Immunology from the College of Medicine at The Ohio State University, and was awarded a National Multiple Sclerosis Society postdoctoral fellowship at Stanford University School of Medicine.

\*\*\*\*\*

### **WIB-San Francisco, Thursday Evening, Sept. 28, 2017**

Topic: "Redefining Healthcare"

Our panel includes moderator, Michelle Zeman, PhD (Clinical Genomics Scientist at Invitae) and the following experts, who will touch upon various aspects of the rapidly growing field of digital health:

- Deborah Kilpatrick, PhD (CEO, Evidation Health)
- Ida Shum, JD (Sr. Manager, Business Development at Samsung)
- Ruchita Sinha (Sr. Director Investments, Sanofi Ventures)
- Lucia Soares (VP, Healthcare Technology Programs & Delivery, Johnson & Johnson)

Date and Time: Thursday, September 28, 2017, 5:15 p.m. – 8:30 p.m. PST  
5:15 p.m. - 6:15 p.m. Registration and Networking

6:15 p.m. - 6:30 p.m. Welcome Remarks  
6:30 p.m. - 8:00 p.m. Panel Discussion and Q&A  
8:00 p.m. - 8:30 p.m. Networking and Wrap Up  
Location: Foley and Lardner, 975 Page Mill Road, Palo Alto, CA 94304

Price: Members: \$20  
Non-Members: \$50  
Students: \$10\*

\* - Students, please email [sanfrancisco@womeninbio.org](mailto:sanfrancisco@womeninbio.org) to obtain the discount code to receive student pricing. Also, note that only 6 tickets are available at the discounted student price.

Details and registration available at  
<http://www.womeninbio.org/events/EventDetails.aspx?id=1007455&group=>

Registration Deadline  
September 26, 2017

#### Topic Description

Digital health is at the forefront of disrupting and positively transforming the current healthcare system. This convergence of traditional pharmaceutical science and technology is progressing toward fundamentally shifting how we track and manage health to improve patient outcomes and promote wellness. Join the San Francisco Bay Area chapter of Women In Bio on September 28 to hear about:

- How and why digital health is transformative
- Where is the money? What interests digital health investors
- What are the recent breakthrough technologies and who are the rising stars in digital health
- Where are the employment opportunities

\*\*\*\*\*

### **JLABS, Tuesday Morning, Oct. 3, 2017**

Event: Meet with... Novo Ventures  
Speaker: Peter Moldt, Ph.D., Partner, Novo Ventures  
Participating representatives  
Peter Moldt | Partner, Novo Ventures  
Kenneth Harrison | Sr Associate, Novo Ventures  
Date and Time: Tuesday, October 3, 2017, 10:30 am  
Agenda

10:30 AM | Registration and Networking  
11:00 AM | Presentation and Q&A  
11:45 AM | Networking Lunch  
1:00 PM | Program Close  
1:00-5:00 PM | One-on-one Meetings\*

\*Companies must apply for a one-on-one meeting ahead of time and be approved. The application period ends on September 6th.

Location: JLABS @ SSF, 329 Oyster Point Blvd, 3rd Floor, South San Francisco, CA  
Fees \$25 | Presentation & Lunch

FREE | 1-on-1 Application

#### Program overview

Do you want to meet with one of the most active Life Science investors in the World? Novo Ventures is the venture investment vehicle for Novo A/S – a holding and investment company that manages ~\$45B of assets on behalf of the Novo Nordisk Foundation.

Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due September 6th. [Apply Here](#).

[http://r20.rs6.net/tn.jsp?f=001m98NlmtMh6VKoS8LXPqNtVKF3hY1\\_uEwZB6HmF8Y-GoeWGrHvynXUOlzxCtra1HLXnby75b\\_FnZwyd7pQI87Jxs2qahhnJkcE1Kkgy6fxExtreaKox4rcqv8OpC3JT24izkU2u3oyD7n9ut2Vg06FOSYMUz4xfKCfZky3xUIN6MYktmk07ZSjQtk aZ2vj2WlXplu6fTZvrHcQ3zKJP\\_bUxMWjGTLJcEK76qxH1vEhHdB7Sr\\_ iyPOS-8Suak-Ub8bNULkb16heaZmjRswHZZ5kSeqNMgr5dmJ&c=JtsptXrUwFmB37fCrXetXYPhPr7DN7FNady1nHNPV8zYr7xUn7re\\_w==&ch=U55Vv8DstNx5o7FGRomWV\\_HPpAbP8-KV66O2ZcdAWJ-81SBNB0EBjw==](http://r20.rs6.net/tn.jsp?f=001m98NlmtMh6VKoS8LXPqNtVKF3hY1_uEwZB6HmF8Y-GoeWGrHvynXUOlzxCtra1HLXnby75b_FnZwyd7pQI87Jxs2qahhnJkcE1Kkgy6fxExtreaKox4rcqv8OpC3JT24izkU2u3oyD7n9ut2Vg06FOSYMUz4xfKCfZky3xUIN6MYktmk07ZSjQtk aZ2vj2WlXplu6fTZvrHcQ3zKJP_bUxMWjGTLJcEK76qxH1vEhHdB7Sr_ iyPOS-8Suak-Ub8bNULkb16heaZmjRswHZZ5kSeqNMgr5dmJ&c=JtsptXrUwFmB37fCrXetXYPhPr7DN7FNady1nHNPV8zYr7xUn7re_w==&ch=U55Vv8DstNx5o7FGRomWV_HPpAbP8-KV66O2ZcdAWJ-81SBNB0EBjw==)

[http://r20.rs6.net/tn.jsp?f=001m98NlmtMh6VKoS8LXPqNtVKF3hY1\\_uEwZB6HmF8Y-GoeWGrHvynXUPZldooFkfgQ\\_eQ6kik64Gop6fbw1r5yKjdxJ59BRGI7pPdRjgRd81yJWU4AYdds3ozLR8TS84dM0aWOAZgI1hE\\_1USOZFGJg8pomY0nh0nZq6YthoTWGa5PGaqbH-RHadUy\\_m\\_E1rox&c=JtsptXrUwFmB37fCrXetXYPhPr7DN7FNady1nHNPV8zYr7xUn7re\\_w==&ch=U55Vv8DstNx5o7FGRomWV\\_HPpAbP8-KV66O2ZcdAWJ-81SBNB0EBjw==](http://r20.rs6.net/tn.jsp?f=001m98NlmtMh6VKoS8LXPqNtVKF3hY1_uEwZB6HmF8Y-GoeWGrHvynXUPZldooFkfgQ_eQ6kik64Gop6fbw1r5yKjdxJ59BRGI7pPdRjgRd81yJWU4AYdds3ozLR8TS84dM0aWOAZgI1hE_1USOZFGJg8pomY0nh0nZq6YthoTWGa5PGaqbH-RHadUy_m_E1rox&c=JtsptXrUwFmB37fCrXetXYPhPr7DN7FNady1nHNPV8zYr7xUn7re_w==&ch=U55Vv8DstNx5o7FGRomWV_HPpAbP8-KV66O2ZcdAWJ-81SBNB0EBjw==)

Novo Ventures is structured as an evergreen fund with an annual total of \$350M to invest in private and public life science companies in North America and Europe. Their team identifies opportunities by leveraging a local presence in leading global biotech hubs and typically co-invests with other life sciences funds as either a lead or co-lead investor.

Novo Ventures has a strong focus on pre-commercial therapeutics and commercial med-tech companies, with opportunistic investments in diagnostics and research tools. Their team of professionals in Boston, Copenhagen, London and San Francisco has an active portfolio of more than 50 companies and has invested in more than 140 companies since 2000.

Peter Moldt, Ph.D., Partner and Kenneth Harrison, Ph.D., Senior Associate with Novo Ventures, will be in attendance to provide an overview presentation on Novo Ventures' key areas of interest and venture investment philosophy. Novo Ventures will also be meeting one-on-one with selected companies.

#### Speaker spotlight

Peter joined Novo Ventures in San Francisco, California in 2012. He is Chairman of the Board of Directors of Allakos and a member of the Board of Directors of Corvus Pharmaceuticals, Bolt Therapeutics, E-Scape Bio, Spruce Biosciences and Tioma Therapeutics. Previously, he was a board member of Cytochroma, HemoFocus, Neurokey and Orphazyme. In 2004, Peter co-founded Curalogic A/S, served as CEO until 2009 and took the company public in 2006. From 2000-2004, he was Chief Operating Officer of 7TM Pharma A/S, which he also co-founded. Previously, he worked for 11 years with NeuroSearch A/S, where he was responsible for all aspects of pre-clinical and clinical drug development. Peter holds a Ph.D. in medicinal

chemistry from the Royal Danish School of Pharmacy. He has also been a post doc with Yale University's department of organic chemistry.

[http://r20.rs6.net/tn.jsp?f=001m98NlmtMh6VKoS8LXPqNtVKF3hY1\\_uEwZB6HmF8Y-GoeWGrHvynXUKsoSrsU0nwnKV8xCh-7lkLTVF3jVmJjarxI5BNBPTWwKfLECT2TnfouEhIUc8YOjx6Ipkp7QsCWPKQGoka9s7Jo0Fbc2blgfvO96TaZKyoYqajQauVk8UL5fRCPSVhgYHrfSx5Fe5WUgBEUZba4c0g=&c=JtsptXrUwFmB37fCrXetXYPhPr7DN7FNady1nHNPV8zYr7xUn7re\\_w==&ch=U55Vv8DstNx5o7FGRomWV\\_HPpAbP8-KV66O2ZcdAWJ-81SBNB0EBjw==](http://r20.rs6.net/tn.jsp?f=001m98NlmtMh6VKoS8LXPqNtVKF3hY1_uEwZB6HmF8Y-GoeWGrHvynXUKsoSrsU0nwnKV8xCh-7lkLTVF3jVmJjarxI5BNBPTWwKfLECT2TnfouEhIUc8YOjx6Ipkp7QsCWPKQGoka9s7Jo0Fbc2blgfvO96TaZKyoYqajQauVk8UL5fRCPSVhgYHrfSx5Fe5WUgBEUZba4c0g=&c=JtsptXrUwFmB37fCrXetXYPhPr7DN7FNady1nHNPV8zYr7xUn7re_w==&ch=U55Vv8DstNx5o7FGRomWV_HPpAbP8-KV66O2ZcdAWJ-81SBNB0EBjw==)

\*\*\*\*\*

### **JLABS, Wednesday Morning, Oct. 4, 2017**

Topic: "Let's Talk Legal Workshop | Protecting and Leveraging your Intellectual Property"

Speakers: Stuart Wilks | Assistant General Council, Johnson & Johnson, Megan R. Baca | Partner, Ropes & Gray and Melissa S. Rones | Partner, Ropes & Gray

Date and Time: Wednesday, October 4, 2017 from 10:30 AM to 1:00 PM (PDT)

Agenda:

10:30 AM - 11:00 AM | Registration & Networking

11:00 AM - 11:45 AM | Presentation

11:45 AM - 12:00 PM | Q&A

12:00 PM - 1:00 PM | Lunch and Networking

1:00 PM | Program Close

Location: JLABS @ SSF, 329 Oyster Point Blvd. Floor 3, South San Francisco, CA 94080

Fees:

\$25 | General Public

\$10 | Student/Academic

\$35 | At the door

\*\* Please note: fees do not go to the presenting lawyers, they cover only a portion of catering and event costs

Register at <https://www.eventbrite.com/e/lets-talk-legal-workshop-protecting-and-leveraging-your-intellectual-property-tickets-35577694843?aff=weekly>

Join us for "Let's Talk Legal Workshop I Protecting your Intellectual Property" – a workshop designed to help entrepreneurs demystify the legal landscape and fill in the blanks. The program is interactive and informal so bring your questions with you!

#### Program Overview

Science and technology both play a key part in your life sciences business. You have technology or information that no one else does. You want to share the secret sauce, but only on your terms. How do you make this happen?

This practical session will focus on how intellectual property (IP) can be used in your life science business, including:

Identifying the types of IP relevant to your business

Protecting and managing IP of your business

Leveraging your IP through collaborations and licensing

What investors look for in IP due diligence and how to avoid common pitfalls

This event is brought to you by Johnson & Johnson's law department working in close partnership with Ropes & Gray LLP, a preeminent global law firm with deep expertise in life sciences. The lawyers presenting these workshops have extensive experience working with life sciences companies ranging from very early-stage ventures through to global companies.

#### Speaker Bios

Stuart Wilks | Assistant General Counsel, Johnson & Johnson

Stuart is Assistant General Counsel at Johnson & Johnson resident at the Johnson & Johnson Innovation Center in Menlo, Park California. In this role, Stuart provides general legal advice to the Innovation Center team in California, participates directly as legal counsel in Innovation Center transactions, and/or coordinates with colleagues in the Johnson & Johnson Law Department to support Innovation Center matters.

During his nearly fifteen years with Johnson & Johnson, in addition to the California Innovation Center, Stuart has supported a diverse group of Johnson & Johnson operating companies and units, such as Alza, BabyCenter, Janssen Health Innovation, Janssen Research & Development, Janssen Supply Chain, Johnson & Johnson Innovation – JJDC, Inc., Noramco, and Scios in a broad range of business and contractual matters. Prior to joining Johnson & Johnson, Stuart was corporate counsel at Scios, Inc. in Fremont, California, corporate counsel at COR Therapeutics, Inc. in South San Francisco, California and an associate in the corporate and life sciences practice groups of the Palo Alto office of Cooley LLP.

Megan R. Baca | Partner, Ropes & Gray

Megan is a partner in Ropes & Gray's intellectual property transactions, life sciences, and technology, media & telecommunications practice groups. Megan advises public and private companies, investors, and universities in strategic transactions where technology or IP assets are the key drivers. These transactions include technology licensing and transfer, development collaborations, joint ventures, and arrangements for supply, distribution, promotion, outsourcing, and other strategic relationships. Megan also represents private equity firms and other companies in technology-focused mergers and acquisitions, and represents venture-backed companies in financings and ongoing matters. Megan also advises clients on data use, digital health, social media, and advertising issues.

With a background in computer science, Megan works with companies in a broad range of industries including technology, software, advertising, gaming, branded products, media, pharmaceutical, biotechnology, medical device, and finance.

Connect with Megan: [Connect on LinkedIn](#)

Melissa S. Rones | Partner, Ropes & Gray

Melissa counsels life sciences clients on a wide range of intellectual property issues, including patent portfolio strategy and life cycle management, licensing and monetization strategy, and the risks associated with third party intellectual property. She also performs due diligence investigations and advises clients on strengths, weaknesses, and opportunities to mitigate risk and remedy issues related to intellectual property in the context of a range of transactions, including private financings and capital markets transactions, license agreements, collaborations, joint ventures, and mergers and acquisitions.

Prior to joining the firm, Melissa completed a Ph.D. in cell and developmental biology from Harvard University. Her graduate work focused on examining signaling events involved during the patterning of tissues to generate complex organs and helped define specific roles for Notch signaling in both cardiogenesis and nephrogenesis.

\*\*\*\*\*

### **QB3 SBIR Workshop At Berkeley, Starting Oct. 4, 2017**

#### Description

"The Art, Science, and Politics of Writing a Successful SBIR Proposal"

Schedule (all classes are on Wednesdays. Location is 177 Stanley Hall, UC Berkeley)

*Oct. 4, 2 - 5 pm*

*Oct. 11, 2 - 5 pm*

*Oct. 25, 2 - 5 pm*

*Nov. 1, 2 - 5 pm*

The chances of your SBIR getting funded are vastly improved if your proposal is well written and packaged. In fact, many great ideas fail to get funded simply because of poor "grantsmanship." In addition, first-time applicants are often daunted by the intricacies of the grant submission and review process, and unsure about how to interact with funding agency staff.

This workshop will help you develop a compelling, well-organized research plan, and to explain your ideas in clear, engaging writing that will win over your reviewers. We will focus on the Research Plan sections of NIH and NSF SBIR proposals, and one full session will be devoted to helping you craft your Specific Aims (the most important section of your application). We will also provide guidance on filling out your budget, Biosketch and other forms, and tips on how to most effectively navigate the NIH and NSF application and review processes.

The workshop will consist of four 2.5 to 3 hour sessions. Specific topics to be covered will include:

- Introduction to the NIH and NSF SBIR funding processes
- Identifying funding opportunities
- Developing a logical, compelling Research Plan
- Facing and conquering the blank page
- Writing for your reviewers
- Instructor and peer feedback on your Specific Aims
- Making the most of graphics
- Electronic registration and submission
- Communicating with NIH and NSF staff

This class is designed for applicants planning to submit for the December 2017 NSF deadline, the January 5 2018 NIH deadline, or later deadlines. The science writing skills taught in this class will serve you well in writing not only grant applications, but

also manuscripts and public relations materials.

Details and registration at <https://www.eventbrite.com/e/qb3-sbir-workshop-at-berkeley-fall-2017-tickets-37132418062?aff=erellivmlt>

#### Fee Structure

General Admission: \$750

Startup in a Box members: \$100

Note: Startup in a Box fee for UC founder: \$250, non-UC founder: \$350. More information on the program is available [here](#).

Email [Ioana Aanei](mailto:Ioana.Aanei) with any questions.

#### About the Instructor

Gabrielle G. Leblanc, Ph.D. is a grant consultant and science writer with over 15 years of previous experience as both an NIH grant program director and an NIH- and NSF-funded PI. She has worked with numerous grant applicants in both academia and biotech, and as a science writer for NIH institutes, non-profit foundations, and the popular press. She has a B.A. in Biology from Harvard University and a Ph.D. in Neuroscience from Stanford University.

\*\*\*\*\*

#### **PBSS, Wednesday, Oct. 11, 2017**

Minisymposium Topic: "Immunogenicity of Biologic Therapeutics"

Speakers: TBA

Organizers:

Date and Time: 10/11/2017, 8:45-17:00

Registration fee (USD): Regular: \$195; Academic: \$125; Students & Unemployed: \$35;

Location: Crowne Plaza, Foster City, CA

Major Sponsor:

Vendor show vendors registered to date: (2)AIT Bioscience; Science Exchange

Registration: <http://www.PBSS.org>

Registration deadline: 10/9/2017 (it will close sooner if the seating cap is reached)

About the Topic

#### Outline:

Introduction to Immunogenicity

Overview of the Immune System

Innate vs Adaptive

Cellular vs Humoral

Antibody classes

Types of Cellular Immune Responses

Immunogenicity Risk Assessment

Route of administration

Correlation of ADAs with safety, PK, efficacy  
Association of ADAs with genotype, protein function, CRIM status  
Clinical Implications  
The Complement System and Pathways  
Immune Complexes  
Hypersensitivity Reactions

\*\*\*\*\*

**PBSS, Tuesday Morning, Oct. 24, 2017**

PBSS-San Francisco Bay Workshop "Good Laboratory Practices (GLPs): Fundamentals, Regulatory Trends and Best Practices"

Speaker: Lisa Helmonds, Vice President, MWA Consulting, Inc.

Date and Time: Tuesday, 10/24/2017, 8:30-12:30

8:45-9 am PBSS Welcome & Workshop Overview

9-9:30 am History of GLP Regulations

9:30-9:45 am Areas Covered by GLPs

9:45-10 am Key Definitions

10-10:15 am Break & Vendor Show

10:15-11:15 am Important Aspects of GLPs

- Subpart A: General Provisions
- Subpart B: Organization and Personnel
- Subparts C & D: Facilities and Equipment
- Subpart E: Testing Facilities Operations
- Subpart F: Test and Control Articles
- Subpart G: Protocol
- Subpart J: Records and Reports
- Subpart K: Disqualification

11:15 -11:30 am FDA Actions and Misconduct

11:30-12 pm Q & A

Registration fee (US\$): Regular: \$125; Academic: \$75; For unemployed or students: \$25; For major-sponsor rep (incl lunch): \$0; For vendor-show reps: \$25; For others, details available upon online login.

Location: SF Bay Area: Foster City Crowne Plaza

Registration deadline: 10/20/2017 (it will close sooner if the seating cap is reached)

Details and registration at <http://www.pbss.org/asp/eventInfo.aspx?eID=546>

**Workshop Topic**

This workshop will include a discussion on the history of Good Laboratory Practices (GLP) regulations, the importance of the regulations, key definitions, areas covered by the GLPs, a review of the regulations, examples of misconduct and, potential FDA actions. After completing this workshop, participants should be able to understand the origin, purpose, and expectations of the GLP regulations.

**Speaker Bio**

Lisa Helmonds has over 30 years of experience in Manufacturing and Quality Assurance in the pharmaceutical, biotechnology and medical device industries. She has extensive GXP knowledge, has held positions as a manufacturing chemist and QA manager/director as an FTE and as a consultant with several startups and large companies such as Syva, Syntex, Roche Bioscience, Alza, Shire, Gilead, along with many others and she understands the challenges facing the industry. She holds a BS in Zoology and minor in Chemistry from the University of Rhode Island and an MBA from Santa Clara University. She is currently Vice President of MWA Consulting, Inc. where she provides the highest quality of consulting services to MWA clients.

[support@PBSS.org](mailto:support@PBSS.org)  
[www.PBSS.org](http://www.PBSS.org)

\*\*\*\*\*

## **JLABS, Tuesday Morning, Oct. 24, 2017**

Topic: "Excited About Your Story: Tell it Like a TED Pro

Date and Time: Tuesday Morning, October 24, 2017

9:30am |

Location: JLABS @ SSF, 329 Oyster Point Blvd, 3rd Floor, South San Francisco, CA  
Fees

\$35 | General Public

\$20 | Student/Academic

### Program overview

Great leaders tell great stories. Stories have the power to touch people's deepest emotions. And emotions are the wellspring of loyalty, trust, co-operation and action. You will succeed more often, more quickly and more completely as you master the power of stories. And, as a human being, you are a natural born storyteller with full access and rights to the best that story has to offer. In this excellent session, you will learn how to unleash your own innate powers and have others be "Excited About Your Story."

Details and registration at

[http://r20.rs6.net/tn.jsp?f=0014Vr7KTt4HYkT3ScXChii0DLMeywI5tsIFrkMhpfXuJjexrFY8BrCk\\_kKNhICbbCnfqMPvnCMxDxk1rOIjtf9IfmMagWmdpvkbdIM-XnTE3uTdHIZi3uuAR91jppKvEnmh3XzmmhIYHlg0TtoT5BRGJDZO-4dbC8kb6iLGvPmpwzttgCxDrACTSf3vN0NsCYI6&c=7IK8faFTT1QFfDnYW1Mb11LS7Gp0-hKzr\\_4fgrwwOiV46KxBRm-4HA==&ch=oY7vJfNs5oKhHHtZVSAzOqpbDDvrpkwodW-igkScTVk8Y4RKQ0x-jw==](http://r20.rs6.net/tn.jsp?f=0014Vr7KTt4HYkT3ScXChii0DLMeywI5tsIFrkMhpfXuJjexrFY8BrCk_kKNhICbbCnfqMPvnCMxDxk1rOIjtf9IfmMagWmdpvkbdIM-XnTE3uTdHIZi3uuAR91jppKvEnmh3XzmmhIYHlg0TtoT5BRGJDZO-4dbC8kb6iLGvPmpwzttgCxDrACTSf3vN0NsCYI6&c=7IK8faFTT1QFfDnYW1Mb11LS7Gp0-hKzr_4fgrwwOiV46KxBRm-4HA==&ch=oY7vJfNs5oKhHHtZVSAzOqpbDDvrpkwodW-igkScTVk8Y4RKQ0x-jw==)

### Topic Description

Topics covered in the session will include:

Why the ability to tell a compelling story is essential for startups

5 elements of a strategic story

Strategies for pitching in front of various audiences: clinical vs. non-clinical vs. investors

How to embed storytelling into all aspects of your business and pitches

Join John Bates, TED speaker, Leadership & Communications Coach, and storyteller extraordinaire. My, does he have some stories to tell you!

### Speaker Bio

John Bates has spoken, hosted, and coached for over 30 different worldwide TED and TEDx events. His group trainings are world famous and executives from companies like Johnson & Johnson Innovation Labs, Accenture, NASA, IBM, and more, recommend him to their colleagues as the best communications and leadership trainer working today. Long ago John fell in love with the Internet the moment it dawned on him what it would do for communication. Since then he has worked with early stage companies as a Founder or early employee, has been instrumental in raising hundreds of millions of dollars in Venture Capital and has always earned the title Chief Evangelist. He Co-Founded BIGWORDS.com, a dotcom darling which ended up going bust in the dotcom bomb of 2000, and he was the first employee and is a part owner of current Internet powerhouse Goldstar.com. John is a co-author of World Class Speaking in Action, an Amazon best-seller, and loves making a difference for those who make a difference.

